- ISIN
- US09075A1088
- CUSIP
- 09075A108
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Feb 11, 2021
Highlights
- Market Cap
- $804.85M
- Enterprise Value
- $806.50M
- EPS (TTM)
- $0.41
- PE Ratio
- 28.89
- PEG Ratio
- 0.24
- Total Revenue (TTM)
- $576.30M
- Gross Profit (TTM)
- $390.14M
- EBITDA (TTM)
- $98.72M
- Year Range
- $5.81 - $12.30
- Target Price
- $13.00
- ROA (TTM)
- 4.38%
- ROE (TTM)
- 15.08%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BVS Performance Chart
Bioventus Inc. (BVS) is up 59.7% since the beginning of the year. At $12 per share, BVS is trading 3.4% below its 52-week high of $12. Investors who bought $1,000 worth of BVS shares 5 years ago would now be looking at an investment worth $728.
Loading charts...
Returns By Period
Bioventus Inc. (BVS) has returned 59.68% so far this year and 70.44% over the past 12 months.
Bioventus Inc.
- 1D
- -2.78%
- 1M
- 36.87%
- 6M
- 47.95%
- YTD
- 59.68%
- 1Y
- 70.44%
- 3Y*
- 48.33%
- 5Y*
- -6.16%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.42%
- 1M
- 1.94%
- 6M
- 8.74%
- YTD
- 10.66%
- 1Y
- 21.02%
- 3Y*
- 19.50%
- 5Y*
- 11.63%
- 10Y*
- 13.41%
BVS Monthly Returns History
Based on dividend-adjusted daily data since Feb 11, 2021, BVS's average daily return is +0.12%, while the average monthly return is +3.40%. At this rate, an investment would double in approximately 1.7 years.
Historically, 48% of months were positive and 52% were negative. The best month was May 2023 with a return of +167.8%, while the worst month was Nov 2022 at -76.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, BVS closed higher 49% of trading days. The best single day was Feb 28, 2023 with a return of +45.9%, while the worst single day was Nov 8, 2022 at -57.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.59% | 10.72% | 3.99% | 8.11% | -13.78% | 10.93% | 25.85% | 59.68% | |||||
| 2025 | 1.71% | -5.06% | -9.76% | -20.11% | -11.35% | 2.16% | -1.51% | 13.50% | -9.59% | -2.09% | 15.88% | -1.98% | -29.14% |
| 2024 | -17.65% | 6.68% | 12.31% | -23.85% | 68.94% | -14.05% | 21.91% | 43.37% | 18.91% | 13.56% | -9.43% | -14.56% | 99.24% |
| 2023 | -24.90% | 8.67% | -49.77% | -5.61% | 167.82% | 6.84% | 25.26% | -0.55% | -8.33% | 13.03% | 7.24% | 31.75% | 101.92% |
| 2022 | -10.08% | -0.23% | 8.46% | -14.68% | -17.87% | -30.97% | 24.49% | -13.90% | -4.24% | 16.29% | -76.04% | 33.85% | -81.99% |
| 2021 | -19.34% | 25.45% | -5.76% | 23.47% | -1.01% | -11.42% | -6.93% | -2.41% | 6.64% | -17.68% | 16.57% | -4.04% |
Benchmark Metrics
Bioventus Inc. has an annualized alpha of 14.34%, beta of 1.16, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since February 11, 2021.
- This stock participated in 133.35% of S&P 500 Index downside but only 64.21% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 14.34%
- Beta
- 1.16
- R²
- 0.06
- Upside Capture
- 64.21%
- Downside Capture
- 133.35%
Return for Risk
Risk / Return Rank
BVS ranks 80 for risk / return — in the top 80% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Bioventus Inc. (BVS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BVS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.50 | ||
| Sortino ratioReturn per unit of downside risk | -0.34 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.30 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | 2.22 | 2.28 | -0.06 |
| Martin ratioReturn relative to average drawdown | 7.25 | 9.88 | -2.64 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Bioventus Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bioventus Inc. was 95.18%, occurring on May 4, 2023. The portfolio has not yet recovered.
The current Bioventus Inc. drawdown is 38.16%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -95.18%May 2023 | 2y 2mo | — | 5y 5moFeb 2021 - now |
Drawdown Indicators
| BVS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.18% | -56.78% | -38.40% |
Max Drawdown (1Y)Largest decline over 1 year | -27.51% | -9.10% | -18.41% |
Max Drawdown (3Y)Largest decline over 3 years | -55.22% | -18.90% | -36.32% |
Max Drawdown (5Y)Largest decline over 5 years | -94.63% | -25.43% | -69.20% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -38.16% | -0.45% | -37.71% |
Average DrawdownAverage peak-to-trough decline | -56.22% | -10.71% | -45.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.84% | 2.09% | +6.75% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Bioventus Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Bioventus Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BVS, comparing it with other companies in the Medical Devices industry. Currently, BVS has a P/E ratio of 28.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BVS compared to other companies in the Medical Devices industry. BVS currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BVS relative to other companies in the Medical Devices industry. Currently, BVS has a P/S ratio of 1.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BVS in comparison with other companies in the Medical Devices industry. Currently, BVS has a P/B value of 4.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BVS
Add Bioventus Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BVS